We care Mega Lifesciences Public Company Limited (MEGA) Investor Presentation – March 2018
Disclaimer The presentation contains forward-looking statements which are based on MEGAs’ current expectations, estimates and projections about its industry, management’s beliefs and certain assumptions. These forward-looking statements are subject to various risks and uncertainties. No assurance is given that future events will occur or that our assumptions are correct. Actual results may differ materially from those projected. For any further queries please contact: Email : investor@megawecare.com T elephone: +66 27694222 Ext. 4230 Fax: +66 27694244 We care 2
1. Business Overview The journey Business Segments • Mega We Care TM branded products business • Maxxcare TM distribution business • OEM business 2. Financial Overview 3. Leadership and Shareholders 4. Future outlook We care
The journey so far…. Key milestones.. Started as an OEM player and Emerged as a leading branded Started branded and distribution became largest soft gel and international distribution business manufacturer in Southeast Asia player in Southeast Asia • Commissioning of new • Commenced plant in Australia branded products • business Planned manufacturing Established expansion in Thailand Company • manufacturing plant Acquired in Australia Incorporated • Medicrafts brand Successful IPO on SET 2002 2013 1982 1993-94 1985-86 1995-96 2012 2016 • Received approval • Became market leading • Expanded into Vietnam, Acquired Bio-Life from Thai FDA for branded products Myanmar and Cambodia Marketing SDN. BHD. Samut Prakarn facility company in key to sell branded products Malaysia in Thailand Southeast Asian and started distribution • Mega Malee joint venture markets • Began manufacturing business • nifedipine for Berlin Wellness We Care center • Leading distributor of established Pharmaceutical pharmaceutical and OTC Industry Co. Ltd products • Construction of own state-of-art warehouse in • Acquisition of Eugica Myanmar approved brand in Vietnam We care 4
What we do… Mega We Care and Maxxcare are key businesses Mega Lifesciences PCL business segments * OEM Business Branded Products Business Distribution Business We develop, manufacture, In addition to manufacturing our We market, sell and distribute market and sell our own brand of various branded prescription own branded products, our market leading medicinal pharmaceutical products, OTC manufacturing facilities in supplements, prescription and consumer products in Thailand and Australia accept pharmaceutical products and Myanmar, Vietnam and various production orders from THB 2,179 mn OTC products, mainly sold in Cambodia. Our clients include third-party customers. 73.6% THB 3,428 mn developing countries with leading domestic and 48.8% market leading presence in international pharmaceutical and THB 473 mn Southeast Asia and growing consumer goods companies. 6.7% presence in Sub-Saharan Africa. * The information under this segment includes impact from Bio-Life (a newly acquired company in Dec’16 ) and new projects which are in their nascent stage. We care 5
Mega We Care contributes maximum to the business… Mega We Care contributed 53% of total revenue and 76% of total gross profits while Maxxcare contributed 42% of total revenue and 21% of total gross profits in 2017 Revenue by Segments FY2017 Gross profits by Segments FY2017 76.1% 52.9% Mega We Care Mega We Care THB THB 42.2% THB 3,289mn 5,078mn THB Maxxcare Maxxcare 4,320mn 9,597mn OEM OEM 21.0% THB THB 4.9% 4,053mn 907mn 2.9% THB THB 466mn 124mn We care 6
We derive majority of our revenue from Southeast Asia while our reach in African continues to widen Southeast Asia accounts for majority of revenues 1 Revenue Breakdown by Region (FY2017) Myanmar South East Asia Thailand 85% Philippines Vietnam Rest of World Cambodia 15% Malaysia Singapore Indonesia Russia Belarus Kazakhstan Ukraine Mongolia Azerbaijan Uzbekistan Hong Kong Nepal United Arab Emirates India Trinidad Yemen Nigeria Sudan Ethiopia Ghana Uganda Kenya Sri Lanka Rwanda Tanzania Peru Legend Burundi Ausralia Zambia Countries with sales of our branded products Countries with manufacturing or product development capabilities Southeast Asia and Indochina contributed 85% and 76% of our operating revenue in FY2017 1.Revenues exclude other income We care 7
Key value drivers Market leading own consumer health and pharmaceutical 1 brands in fast growing developing markets (Refer to slide 11) Leading distributor of pharmaceutical and OTC products in 2 select frontier markets of Myanmar, Vietnam and Cambodia ( Refer to slide 17) Focused on fast growing markets including a unique established 3 and market leading presence in the Myanmar market (Refer to slide 18) High quality products manufactured in world-class 4 manufacturing facilities accredited by international regulatory agencies (Refer to slide 12) Strong product pipeline driven by an efficient and targeted 5 product development strategy (Refer to slide 15) Proven track record of delivering growth and profitability (Refer 6 to slide 24) Experienced management team instrumental in building the 7 business is significantly invested in the Company (Refer to slide 37) We care 8
1. Business Overview The journey Business Segments • Mega We Care TM branded products business • Maxxcare TM distribution business • OEM business 2. Financial Overview 3. Leadership and Shareholders 4. Future outlook We care
TM Branded products business We sell medicinal supplements, prescription and OTC products within our branded business Categories Description Key Brands • Products which provide health benefits in addition to the basic nutritional value found in normal diet. • Regulation varies across jurisdictions but generally Medicinal regulated for their manufacturing, safety, efficacy, labeling and marketing. supplements • Dermatology , general health/Immunity, gastroenterology, men’s/women health and orthopedics are the key therapeutic categories. • Medicines only available for purchase by consumers with a medical prescription • Strictly regulated by authorities as to their Prescription manufacturing, safety, efficacy, labeling and Products marketing. • Diabetology, dermatology , gastroenterology and orthopedics are the key therapeutic categories. • Medicines sold directly to consumer without a prescription from a healthcare professional. OTC • Analgesics , gastroenterology and cough and cold Products are the key therapeutic categories. We care 10
Our market leading medicinal supplements, branded generic and OTC brands Thailand Vietnam Myanmar Therapeutic Therapeutic Therapeutic Own Brand Rank Own Brand Rank Own Brand Rank Category (TC) Category (TC) Category (TC) #1 Vitamin C #1 Vitamin E #1 Haematinics Nat C Enat Ferrovit Pharyngeal #1 Vitamin B Complex #2 #1 Vitamin E preparation Nat B Eugica candy Enat Anti-atheroma Oral Anti-acne #1 #1 #1 Calcium Supplements Natural Preparation Fish oil Acnotin Calcivita Anti-rheumatics Non- Iron Combination #4 #4 #1 Hepatoprotectant steroidal Products Gofen Ferrovit Livolin Forte #1 Oral Anti-acne Cerebral and #2 #2 Prenatal Preparation Peripheral Vascular Acnotin Giloba Prenatal #3 Emollients and #2 MVMM Protectives NNO Nutrivita Source: Internal assessment and analysis We care 11
World-class manufacturing facilities subordinated to Mega We Care TM branded products Thailand Manufacturing Facility 1 – Soi 6, Samutprakarn • Commenced production in 1985 • Manufactures: Soft gels, Hard gels and Sachets • Approved by German health authorities, the Thai FDA and the Australian TGA Thailand Manufacturing Facility 2 – Soi 8, Samutprakarn • Commenced production in 2009 • Manufactures: Soft gels, Hard gels, Tablets and Sachets • Approved by German health authorities, the Thai FDA and the Australian TGA Australian Manufacturing Facility – Pakenham Facility • Facility replaces the manufacturing facility established in Dandenong, Melbourne • Commenced production in 2 nd quarter 2013 • Manufactures: Hard capsules, Tablets and Powders • Approved by Australian TGA We care 12
Recommend
More recommend
